A Phase 1b-2 Study of Raludotatug Deruxtecan in People With Ovarian Cancer

Full Title

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Purpose

Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.

R-DXd is a type of drug called an antibody-drug conjugate. The antibody binds to a protein on cancer cells called CDH6. The linked drug enters these cells and kills them, with reduced risk of harming other cells.

If your ovarian cancer came back 6 months or more after platinum-containing chemotherapy, you will get R-DXd with paclitaxel. If your ovarian cancer came back within 6 months after platinum-containing chemotherapy, you will get R-DXd with bevacizumab.

Contact

For more information or to see if you can join this study, please call Dr. Paul Johannet’s office at 646-888-5327.